Compositions and methods for detecting Neisseria Gonorroheae

A real-time PCR method using specific primers and FRET technology for detecting Neisseria gonorrhoeae addresses the limitations of current detection methods by ensuring high specificity and sensitivity, effectively distinguishing NG from other Neisseria species.

JP7592027B2Active Publication Date: 2024-11-29F HOFFMANN LA ROCHE & CO AG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021565986
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-07
Filing Date
2020-05-05
Publication Date
2024-11-29
Estimated Expiration
2040-05-05

AI Technical Summary

Technical Problem

Current methods for detecting Neisseria gonorrhoeae (NG) are inadequate, often leading to false negatives and false positives, and lack the ability to differentiate NG from other Neisseria species, particularly in complex biological samples.

Method used

A method involving real-time polymerase chain reaction (PCR) with specific primers and probes targeting the Pilin Inverting protein (Piv) gene of NG, utilizing fluorescence resonance energy transfer (FRET) for detection, including amplification and hybridization steps to ensure specificity and sensitivity.

Benefits of technology

The method provides rapid and accurate detection of NG, minimizing sample contamination and improving diagnostic accuracy by differentiating NG from other Neisseria species, thereby enhancing clinical management and reducing the risk of untreated infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592027000006
    Figure 0007592027000006
  • Figure 0007592027000001
    Figure 0007592027000001
  • Figure 0007592027000002
    Figure 0007592027000002
Patent Text Reader

Abstract

NG Pilin Inverting Protein (Piv) in biological or non-biological samples Ng The present invention discloses a method for rapidly detecting the presence or absence of the Neisseria gonorrhoeae (NG) gene. The method may include performing an amplification step, a hybridization step, and a detection step. Additionally, a primer, NG Piv, designed for the detection of Neisseria gonorrhoeae (NG) is disclosed. Ng Gene-targeted probes are provided, as well as kits.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the field of molecular diagnostics, and more particularly, to the detection of Neisseria Gonorroheae. [Background technology]

[0002] Neisseria gonorrhoeae (NG) or gonococcus, also known as gonococcus, is a species of Gram-negative diplococcus isolated by Albert Neisser in 1879. NG is the causative agent of gonorrhea and is a cytochrome oxidase-positive, nonmotile, nonspore-forming Gram-negative diplococcus. NG is the causative agent of sexually transmitted urogenital gonorrhea, as well as other forms of gonococcal disease, including disseminated gonococcemia, septic arthritis, and neonatal gonococcal ophthalmia. Neisseria gonorrhoeae infects the mucosa of the genital tract, including the cervix, uterus, and fallopian tubes in women, and the urethra in both sexes. Neisseria gonorrhoeae can also infect the mucosa of the mouth, pharynx, eyes, and rectum.

[0003] Gonorrhea is a very common infection. The CDC estimates that approximately 820,000 new cases of gonorrhea occur in the United States each year, with more than half of these infections being detected and reported to the Centers for Disease Control and Prevention (CDC). The CDC estimates that 570,000 of these were in young people aged 15-24. In 2017, 555,608 cases of gonorrhea were reported to the CDC.

[0004] Gonorrhea is transmitted by sexual contact with the penis, vagina, mouth, or anus of an infected partner. Ejaculation is not necessary to transmit or spread gonorrhea. Gonorrhea can also be spread perinatally from mother to infant during birth. People who have had and been treated for gonorrhea can become reinfected if they have sexual contact with someone infected with gonorrhea.

[0005] Gonorrhea is the second most commonly reported infectious disease. Clinical manifestations of NG infection are numerous. Many men with gonorrhea are asymptomatic. When symptomatic, signs and symptoms of urethral infection in men include dysuria or a white, yellow, or green urethral discharge that usually appears 1 to 14 days after infection. Men with gonorrhea may also complain of testicular or scrotal pain if the urethral infection is complicated by epididymitis.

[0006] In women, the primary site of infection is the endocervix. Complications with Chlamydia trachomatis (CT), Trichomonas vaginalis, and vaginitis are highly prevalent; many women remain asymptomatic and therefore do not seek medical care. Even when women do have symptoms, they are often so mild and nonspecific that they are mistaken for bladder or vaginal infections. Early symptoms and signs in women include dysuria, increased vaginal discharge, or vaginal bleeding outside of menstrual periods. Women with gonorrhea are at risk of developing serious complications from the infection, regardless of the presence or severity of symptoms.

[0007] Other sites of gonococcal infection in men and women are the pharynx, conjunctiva, and to a lesser extent, the disease manifests itself as disseminated gonococcal infection. Pharyngeal infection can cause a sore throat, but is usually asymptomatic. Infants can develop conjunctivitis from infected mothers.

[0008] Annual screening for Neisseria gonorrhoeae infection is recommended for all sexually active women under the age of 25 and for older women who are at increased risk for infection (e.g., women with new sexual partners, multiple sexual partners, concurrent sexual partners, or sexual partners with a sexually transmitted infection (STI)).

[0009] If left untreated, gonorrhea can also spread to the blood and cause disseminated gonococcal infection (DGI). DGI is usually characterized by arthritis, tenosynovitis, and / or dermatitis. The condition can be life-threatening. Untreated gonorrhea can increase a person's risk of contracting or transmitting HIV, the virus that causes AIDS.

[0010] Genitourinary gonorrhea can be diagnosed by testing urine, urethral (for men), or endocervical or vaginal (for women) specimens using nucleic acid amplification tests (NAATs).Therefore, there is a need in the art for better and more complete methods to specifically detect NG. Summary of the Invention

[0011] Certain embodiments of the present disclosure relate to methods for rapid detection of the presence or absence of NG in biological or non-biological samples, for example, multiplex detection of NG by real-time polymerase chain reaction in a single test tube. The embodiments include detection methods of CA, which include performing at least one cycling step, which may include an amplification step and a hybridization step. Additionally, the embodiments include primers, probes and kits designed for detection of NG in a single tube. The detection methods are designed to target specific genes in the Neisseria gonorrhoeae genome that have the potential to distinguish it from other Neisseria species.

[0012] A method for detecting Neisseria gonorrhoeae (NG) in a sample, comprising the steps of: performing an amplification step, which, if NG is present in the sample, involves contacting the sample with a set of primers designed to target a specific NG gene and produce an amplification product; performing a hybridization step, which involves contacting the amplification product with a probe for one or more detectable target NG genes; and detecting the presence or absence of a sample amplification product, wherein the presence of an amplification product indicates the presence of NG in the sample and the absence of an amplification product indicates the absence of NG in the sample; and detecting whether the target NG gene is a PILIN Inverting protein (Piv Ng ) gene.

[0013] In one embodiment, a method for detecting NG in a sample, comprising the steps of: detecting a series of NG Piv nucleic acids if NG Piv nucleic acids are present in said sample; Ng performing an amplification step comprising contacting a gene primer with the sample to generate an amplification product; Ng performing a hybridization step comprising contacting a genetic probe with the amplification product, and detecting the presence or absence of the amplification product, the presence of the amplification product indicating the presence of NG in the sample, and the absence of the amplification product indicating the absence of NG in the sample; Ng The gene primer comprises a first primer comprising or consisting of a first oligonucleotide sequence of SEQ ID NO: 1 or its complement, and a second primer comprising or consisting of a second oligonucleotide sequence of SEQ ID NO: 2 or its complement; Ng Methods are provided in which the genetic probe comprises a third oligonucleotide sequence of SEQ ID NO: 3 or its complement. In certain embodiments, the method for detecting NG further comprises contacting the sample with a set of primers and probes for amplifying and detecting NGDR9 gene sequences as disclosed in U.S. Patent No. 7,476,736, the entire contents of which are incorporated herein by reference.

[0014] In some embodiments, the hybridization step comprises the step of generating a detectable NG Piv labeled with a donor fluorescent moiety and a corresponding acceptor moiety. Ng The method includes contacting the genetic probe with the amplification product, and the detection step includes detecting the presence or absence of fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor moiety of the probe, where the presence or absence of fluorescence indicates the presence or absence of NG in the sample. In some embodiments, the amplification and hybridization steps are repeated, where the number of repetitions depends, for example, on the nature of the sample. If the sample is a complex mixture of nucleic acids, more amplification and hybridization steps will be required to amplify the target sequence enough for detection. In some embodiments, the amplification and hybridization steps are repeated at least about 20 times, but may be repeated at least 25, 30, 40, 50, 60 or even 100 times. Furthermore, detection of the presence or absence of the amplification product can be performed during or after each amplification and hybridization step, during or after every other amplification and hybridization step, during or after a particular amplification and hybridization step, or during or after a particular amplification and hybridization step, where sufficient amplification product is expected to be present for detection, if any. In some embodiments, the amplification step uses a polymerase enzyme with 5' to 3' nuclease activity. In some embodiments, the donor fluorescent moiety and the corresponding acceptor moiety are within 8 to 20 nucleotides of each other on the probe. In some embodiments, the acceptor moiety is a quencher. In some embodiments, the oligonucleotide comprises or consists of a sequence of nucleotides selected from SEQ ID NOs: 1-3, or a complement thereof, having 100 nucleotides or less, 50 nucleotides or less, 40 nucleotides or less, or 30 nucleotides or less. In some embodiments, the first and second NG Piv Ng Gene primers and detectable NG Piv NgThe gene probe has 40 or fewer nucleotides (eg, 35 or fewer nucleotides, 30 or fewer nucleotides).

[0015] In another embodiment, the disclosure provides oligonucleotides comprising a nucleic acid having at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90% or 95%) to one of SEQ ID NOs: 1-3 or their complements, the oligonucleotide having 100 or fewer nucleotides. Generally, these oligonucleotides may be primer nucleic acids, probe nucleic acids, etc. in these embodiments. In some embodiments, the oligonucleotide comprises at least one modified nucleotide, e.g., to alter nucleic acid hybridization stability compared to an unmodified nucleotide. In some embodiments, the at least one modified nucleotide is N 6 -Benzyl-dA,N 4 -Benzyl-dC,N 6 -para-tert-butyl-benzyl-dA, and N 4 -para-tert-butyl-benzyl-dC. Optionally, the oligonucleotide comprises at least one label and / or at least one quencher moiety. In some embodiments, the oligonucleotide comprises at least one conservatively modified variation. A "conservatively modified variation" or simply "conservative variation" of a particular nucleic acid sequence refers to a nucleic acid that encodes an identical or essentially identical amino acid sequence, or, if the nucleic acid does not encode an amino acid sequence, an essentially identical sequence. Those skilled in the art will recognize that individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small number of amino acids (typically less than 5%, more typically less than 4%, 2% or 1%) in the encoded sequence are "conservatively modified variations" in which the modification results in the deletion of an amino acid, the addition of an amino acid, or the replacement of an amino acid with a chemically similar amino acid. In some embodiments, at least one of the first and second target NG gene primers and the detectable target NG gene probe comprises at least one modified nucleotide.

[0016] In some embodiments, the amplification (amplification step) can use a polymerase enzyme with 5' to 3' nuclease activity. Thus, the donor fluorescent moiety and the acceptor moiety, e.g., a quencher, can be within 5 to 20 nucleotides (e.g., 8 or 10) of each other along the length of the probe. In another aspect, the detectable probe includes a nucleic acid sequence that allows for the formation of a secondary structure. The formation of such a secondary structure generally results in spatial proximity between the first fluorescent moiety and the second fluorescent moiety. According to the method, the second fluorescent moiety on the probe can be a quencher.

[0017] The present disclosure provides methods for detecting the presence or absence of Neisseria gonorrhoeae (NG) in a biological sample from an individual. Such methods generally include performing at least one cycling step, including an amplification step and a dye-binding step. Typically, the amplification step includes contacting the sample with a plurality of primer pairs designed to target specific NG genes to generate one or more target NG gene amplification products if a target NG gene nucleic acid molecule is present in the sample, and the dye-binding step includes contacting the target NG gene amplification products with a double-stranded DNA binding dye. In one embodiment, the target NG gene is NG Piv. Ng The target NG gene is a gene. Such a method also includes detecting the presence or absence of binding of a double-stranded DNA binding dye to the amplification product, the presence of binding indicates the presence of NG gene in the sample, and the absence of binding indicates the absence of NG in the sample. An exemplary double-stranded DNA binding dye is ethidium bromide. Furthermore, such a method can also include determining the melting temperature between the target NG gene amplification product and the double-stranded DNA binding dye, and the melting temperature confirms the presence or absence of NG. In certain embodiments, the method for detecting the presence or absence of NG in a biological sample from an individual further includes performing amplification using a set of primers for amplifying NGDR9 gene sequence.

[0018] In yet another embodiment, NG Piv NgA kit for detecting the gene is provided. The kit includes: Ng One or more sets of primers specific for gene amplification and NG Piv Ng and one or more detectable probes specific for detecting gene amplification products. In one embodiment, the kit further comprises one or more sets of primers and probes for amplifying and detecting NGDR9 gene sequences.

[0019] In particular, the oligonucleotide primers and probes disclosed above in connection with the method according to the present invention are suitable for inclusion in the kit according to the present invention. Herein, a Piv of NG comprising a first primer comprising or consisting of a first oligonucleotide sequence of SEQ ID NO: 1 or its complement; a second primer comprising or consisting of a second oligonucleotide sequence of SEQ ID NO: 2 or its complement; and a fluorescently detectably labeled probe comprising or consisting of a third oligonucleotide sequence of SEQ ID NO: 3 or its complement, the detectably labeled probe being configured to hybridize to the amplicon generated by the first primer and the second primer is described. NgA kit for detecting genes is provided. In one aspect, the kit can include a donor moiety and a corresponding acceptor moiety, such as a probe that is already labeled with another fluorescent moiety or a dark quencher, or can include a fluorophore moiety for labeling the probe. The kit can also further include at least one nucleoside triphosphate, a nucleic acid polymerase, and a buffer required for the function of the nucleic acid polymerase. The kit can also include a package insert and instructions for using the primers, probes, and fluorophore moieties to detect the presence or absence of NG in a sample. In some embodiments, the detectably labeled third oligonucleotide sequence includes a donor fluorescent moiety and a corresponding acceptor moiety. In some embodiments, the acceptor moiety is a quencher. In some embodiments, at least one of the first, second, and third oligonucleotides includes at least one modified nucleotide. In some embodiments, the at least one modified nucleotide is N 6 -Benzyl-dA,N 4 -Benzyl-dC,N 6 -para-tert-butyl-benzyl-dA, and N 4 -para-tert-butyl-benzyl-dC, In some embodiments, the first, second and third oligonucleotides have 40 or fewer nucleotides.

[0020] In another aspect, a composition is provided that includes a set of oligonucleotide primers for amplifying a target NG gene as disclosed above. In some embodiments, a set of NG Piv Ng The gene primer comprises a first primer comprising or consisting of a first oligonucleotide sequence of SEQ ID NO:1 or its complement, and a second primer comprising or consisting of a second oligonucleotide sequence of SEQ ID NO:2 or its complement. In certain embodiments, the composition comprises a detectable NG Piv comprising or consisting of a third oligonucleotide sequence of SEQ ID NO:3 or its complement. Ng It further comprises a gene probe.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Methods and materials similar or equivalent to those described herein can be used in the practice or testing of this subject, but suitable methods and materials are described below.In addition, materials, methods, and examples are only illustrative and are not intended to be limiting.All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.In case of conflict, the present specification, including definitions, will control.

[0022] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the drawings and detailed description, and from the claims. [Brief description of the drawings]

[0023] [Figure 1] Figure 1 shows PCR growth curves for real-time PCR experiments generated from NG PivNg primers and probes with concentrations of genomic Neisseria gonorrhoeae DNA template from strain #2949 present at genome equivalent concentrations (ge / PCR) of 30,000 (NG-2949-Neat), 3,000 (NG-2949-DF10-D1), 300 (NG-2949-DF10-D2), 30 (NG-2949-DF10-D3) and 3 (NG-2949-DF10-D4) per PCR reaction. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Diagnosis of NG infection by nucleic acid amplification provides a method for rapid and accurate detection of infection. A real-time assay for detecting NG in a sample is described herein. Primers and probes for detecting NG are provided, and articles of manufacture or kits containing such primers and probes are also provided. The increased sensitivity of real-time PCR for the detection of NG compared to other methods, and the improved features of real-time PCR, including sample containment and real-time detection of amplified products, make the implementation of this technology feasible for routine diagnosis of NG infection in clinical laboratories.

[0025] The present disclosure includes oligonucleotide primers and fluorescently labeled hydrolysis probes that hybridize to specific loci in the NG genome to specifically identify NG using TaqMan® amplification and detection technology. Target selection for NG required a comprehensive search of public sequence databases as well as a literature search for NG targets that could identify the nearest neighbors Neisseria meningitidis and Neisseria lactamica. Multiple targets from public sequence databases were analyzed in the target selection process, and many showed cross-reactivity with other Neisseria species. Additionally, sequences in public databases are complicated by "bulk" sequence data from multicopy targets. Analysis revealed that the selected target NG gene was associated with the NG Pilin Inverting protein (Piv Ng ) gene (GenBank accession no. U65994.1, residues 3603-4577).

[0026] The disclosed method may include performing at least one cycling step that includes amplifying one or more portions of a nucleic acid molecule gene target from a sample using one or more primer pairs. As used herein, "primer(s)" refers to an oligonucleotide primer that specifically anneals to a target gene in NG and initiates DNA synthesis therefrom under appropriate conditions to produce a respective amplification product. Each of the primers considered anneals to a target within or adjacent to a respective target nucleic acid molecule such that at least a portion of each amplification product contains a nucleic acid sequence corresponding to the target. If one or more of the target NG gene nucleic acids are present in the sample, one or more amplification products are generated, and thus the presence of one or more target NG gene amplification products indicates the presence of NG in the sample. The amplification products must contain a nucleic acid sequence complementary to one or more detectable probes of the target NG gene. As used herein, "probe(s)" refers to an oligonucleotide probe that specifically anneals to a nucleic acid sequence encoding the target NG gene. The cycling step includes an amplification step, a hybridization step, and a detection step, in which the sample is contacted with one or more detectable probes to detect the presence or absence of NG in the sample.

[0027] The term "amplifying" as used herein refers to the process of synthesizing a nucleic acid molecule complementary to one or both strands of a template nucleic acid molecule. Amplifying a nucleic acid molecule typically involves denaturing the template nucleic acid, annealing a primer to the template nucleic acid at a temperature below the melting temperature of the primer, and enzymatically extending from the primer to generate an amplification product. Amplification typically requires the presence of deoxyribonucleoside triphosphates, a DNA polymerase enzyme (e.g., Platinum® Taq), and an appropriate buffer and / or cofactors for optimal activity of the polymerase enzyme (e.g., MgCl2 and / or KCl).

[0028] The term "primer" as used herein is known to those skilled in the art and refers to an oligomeric compound, primarily oligonucleotides, but also modified oligonucleotides that can "prime" DNA synthesis by a template-dependent DNA polymerase, i.e., for example, the 3' end of the oligonucleotide provides a free 3'-OH group, whereby a deoxynucleoside triphosphate is used, to which further "nucleotides" can be attached by the template-dependent DNA polymerase, which establishes a 3' to 5' phosphodiester bond, thereby releasing pyrophosphate. Thus, there is no fundamental difference between a "primer", an "oligonucleotide", or a "probe", except perhaps in the intended function.

[0029] The term "hybridizing" refers to the annealing of one or more probes to an amplification product. Hybridization conditions typically include a temperature below the melting temperature of the probe, but which avoids non-specific hybridization of the probe.

[0030] The term "5'-3' nuclease activity" refers to the activity of a nucleic acid polymerase typically associated with nucleic acid chain synthesis whereby nucleotides are removed from the 5' end of a nucleic acid chain.

[0031] The term "thermostable polymerase" refers to a polymerase enzyme that is thermostable, that catalyzes the formation of primer extension products complementary to a template, and that does not irreversibly denature when exposed to elevated temperatures for the time required to effect denaturation of the double-stranded template nucleic acid. Generally, synthesis is initiated at the 3' end of each primer and proceeds in the 5' to 3' direction along the template strand. Thermostable polymerases have been isolated from Thermus flavus, T.ruber, T.thermophilus, T.aquaticus, T.lacteus, T.rubens, Bacillus stearothermophilus, and Methanothermus fervidus. Nevertheless, non-thermostable polymerases can also be used in PCR assays if the enzyme is supplemented.

[0032] The term "complement thereof" refers to a nucleic acid that is the same length as and exactly complementary to a given nucleic acid.

[0033] The term "extension" or "lengthening" when used in reference to a nucleic acid refers to when additional nucleotides (or other similar molecules) are incorporated into a nucleic acid. For example, a nucleic acid is optionally extended by a nucleotide incorporating biocatalyst, such as a polymerase, which typically adds nucleotides to the 3' end of the nucleic acid.

[0034] The terms "identical" or "percent identity" in the context of two or more nucleic acid sequences refer to two or more sequences or subsequences that are identical or have a certain percentage of identical nucleotides, when compared or aligned for maximum correspondence as determined, for example, using one of the sequence comparison algorithms available to those of skill in the art or by visual inspection. Exemplary algorithms suitable for determining percent sequence identity and sequence similarity are the BLAST programs, see, e.g., Altschul et al. (1990) "Basic local alignment search tool," J. Mol. Biol. 215:403-410; Gish et al. (1993) "Identification of protein coding regions by database similarity search," Nature Genet. 3:266-272; Madden et al. (1996) "Applications of network BLAST server," Meth. Enzymol. 266:131-141; Altschul et al. (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," Nucleic Acids Res. 25:3389-3402; and Zhang et al. (1997) "PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation," Genome Genet. Res. 7:649-656, which are incorporated herein by reference.

[0035] "Modified nucleotide" in relation to oligonucleotide refers to the change in which at least one nucleotide of an oligonucleotide sequence is replaced by a different nucleotide that provides the oligonucleotide with desired properties.Exemplary modified nucleotides that can be replaced in the oligonucleotide described herein include, for example, C5-methyl-dC, C5-ethyl-dC, C5-methyl-dU, C5-ethyl-dU, 2,6-diaminopurine, C5-propynyl-dC, C5-propynyl-dU, C7-propynyl-dA, C7-propynyl-dG, C5-propargylamino-dC, C5-propargylamino-dU, C7-propargylamino-dA, C7-propargylamino-dG, 7-deaza-2-deoxyxanthosine, pyrazolopyrimidine analogs, pseudomimetic-dU, nitropyrrole, nitroindole, 2-O-methylriboU, 2-O-methylriboC, N4-ethyl-dC, N 6 -Methyl-dA,N 6 -Benzyl-dA,N 4 -Benzyl-dC,N 6 -para-tert-butylbenzyl-dA,N 4 -para-tert-butyl-benzyl-dC, etc. Many other modified nucleotides that can be substituted in oligonucleotides are mentioned herein or known in the art. In certain embodiments, modified nucleotide substitutions modify the melting temperature (Tm) of the oligonucleotide compared to the melting temperature of the corresponding unmodified oligonucleotide. To further explain, certain modified nucleotide substitutions can, in some embodiments, reduce non-specific nucleic acid amplification (e.g., minimize primer dimer formation, etc.), increase the yield of intended target amplicon, etc. Examples of these types of nucleic acid modifications are described, for example, in U.S. Patent No. 6,001,611, which is incorporated herein by reference.

[0036] NG detection The present disclosure relates to, for example, NG Piv NgMethods are provided for detecting NG by amplifying a portion of a gene nucleic acid sequence, the nucleic acid sequence of which is publicly available (e.g., GenBank Accession No. U65994.1 residues 3603-4577, SEQ ID NO: 4). Specifically, primers and probes for amplifying and detecting specific NG nucleic acid molecular targets are provided by embodiments of the present disclosure.

[0037] For detection of NG, NG Piv Ng Primers and probes are provided for amplifying genes.Nucleic acids other than those exemplified herein can also be used to detect NG in samples.For example, functional variants can be evaluated for specificity and / or sensitivity by those skilled in the art using routine methods.Representative functional variants can include, for example, one or more deletions, insertions and / or substitutions in the target NG gene nucleic acid disclosed herein.

[0038] More specifically, each of the oligonucleotide embodiments includes a nucleic acid having a sequence selected from SEQ ID NOs: 1-3, a substantially identical variant thereof having at least, e.g., 80%, 90%, or 95% sequence identity to one of SEQ ID NOs: 1-3, or a complement and variant of SEQ ID NOs: 1-3.

[0039] [Table 1]

[0040] In one embodiment, the above-mentioned set of primers and probes are used to provide detection of NG in a biological sample suspected of containing NG. The set of primers and probes comprises or consists of the nucleic acid sequences of SEQ ID NOs: 1 to 3. Ng It may comprise or consist of primers and probes specific to the nucleic acid sequence of the gene. NgThe gene primers and probes comprise or consist of functionally active variants of any of the primers and probes of SEQ ID NOs: 1-3. In yet another embodiment, detection of NG in a biological sample further comprises providing primers and probes specific to the NGDR9 gene sequence (SEQ ID NO: 5) disclosed in U.S. Patent No. 7,476,736, the entirety of which is incorporated herein by reference.

[0041] Functionally active variants of any of the primers and / or probes of SEQ ID NOs: 1-3 can be identified by using the primers and / or probes in the disclosed methods. Functionally active variants of any of the primers and / or probes of SEQ ID NOs: 1-3 relate to primers and / or probes that provide similar or higher specificity and sensitivity in the described methods or kits compared to the respective sequences of SEQ ID NOs: 1-13.

[0042] A variant may vary from the sequence of SEQ ID NO: 1-3 by the addition, deletion or substitution of one or more nucleotides, for example, the addition, deletion or substitution of one or more nucleotides at the 5'-end and / or 3'-end of each of the sequences of SEQ ID NO: 1-3. As detailed above, the primer (and / or probe) may be chemically modified, i.e., the primer and / or probe may contain modified nucleotides or non-nucleotide compounds. Thus, the probe (or primer) is a modified oligonucleotide. A "modified nucleotide" (or "nucleotide analog") differs from a natural "nucleotide" by some modification, but still consists of a base or base-like compound, a pentofuranosyl sugar or pentofuranosyl sugar-like compound, a phosphate moiety or a phosphate-like moiety, or a combination thereof. For example, a "label" may be attached to the base portion of a "nucleotide" to obtain a "modified nucleotide". A natural base in a "nucleotide" may be replaced, for example, with a 7-deazapurine, thus also obtaining a "modified nucleotide". The terms "modified nucleotide" or "nucleotide analog" are used interchangeably in this application. A "modified nucleoside" (or "nucleoside analog") differs from a naturally occurring nucleoside by some modification, as outlined above for "modified nucleotides" (or "nucleotide analogs").

[0043] Target NG Piv NgOligonucleotides, including modified oligonucleotides and oligonucleotide analogs, that amplify nucleic acid molecules encoding genes can be designed using computer programs such as, for example, OLIGO (Molecular Biology Insights Inc., Cascade, Colo.). Important features in designing oligonucleotides to be used as amplification primers include, but are not limited to, an appropriate size of the amplification product to facilitate detection (e.g., by electrophoresis), similar melting temperatures for the members of the pair of primers, and the length of each primer (i.e., the primers must be long enough to anneal with sequence specificity and initiate synthesis, but not so long that fidelity is compromised during oligonucleotide synthesis). Typically, oligonucleotide primers are 8-50 nucleotides long (e.g., 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or 50 nucleotides long). In some embodiments, the oligonucleotide primers are 40 nucleotides long or less.

[0044] In addition to a set of primers, the method may use one or more probes to detect the presence or absence of NG. The term "probe" refers to a synthetically or biologically produced nucleic acid (DNA or RNA) that contains a specific nucleotide sequence that allows it to specifically (i.e., preferentially) hybridize to a "target nucleic acid", in this case the target NG gene nucleic acid, under a defined, predetermined stringency, by design or selection. A "probe" may be referred to as a "detection probe", which means to detect a target nucleic acid.

[0045] In some embodiments, the NG Piv Ng In one embodiment, the genetic probe may be labeled with at least one fluorescent label. NgThe genetic probe may be labeled with a donor fluorescent moiety, e.g., a fluorescent dye, and a corresponding acceptor moiety, e.g., a quencher. In one embodiment, the probe comprises or consists of a fluorescent moiety and the nucleic acid sequence comprises or consists of SEQ ID NO:3.

[0046] The design of oligonucleotides used as probes can be done in a similar manner to the design of primers. Embodiments may use a single probe or a pair of probes for detection of the amplification product. Depending on the embodiment, the probe(s) used may include at least one label and / or at least one quencher moiety. Like primers, the probes usually have similar melting temperatures, and the length of each probe must be sufficient for sequence-specific hybridization to occur, but not so long that fidelity is compromised during synthesis. Oligonucleotide probes are generally 15-40 (e.g., 16, 18, 20, 21, 22, 23, 24, or 25) nucleotides in length.

[0047] The constructs are NG Piv Ng The construct may include a vector containing one of the gene primers and probe nucleic acid molecules. The construct may be used, for example, as a control template nucleic acid molecule. Vectors suitable for use are commercially available and / or produced by recombinant nucleic acid technology methods routine in the art. NG Piv Ng The gene nucleic acid molecule can be obtained, for example, by chemical synthesis, direct cloning from a CA, or by PCR amplification.

[0048] Constructs suitable for use in the present methods are typically NgIn addition to the genetic nucleic acid molecule (e.g., a nucleic acid molecule comprising one or more of the sequences of SEQ ID NOs: 1-3), the vector contains a sequence encoding a selection marker (e.g., an antibiotic resistance gene) for selecting the desired construct and / or transformant, as well as an origin of replication. The choice of vector system usually depends on several factors, including, but not limited to, the choice of host cell, replication efficiency, selectability, inducibility and ease of recovery.

[0049] The construct containing the target NG gene nucleic acid molecule may be propagated in a host cell. The term host cell as used herein is meant to include prokaryotic and eukaryotic organisms, such as yeast, plant and animal cells. Prokaryotic hosts may include E. coli, Salmonella typhimurium, Serratia marcescens and Bacillus subtilis. Eukaryotic hosts include yeasts such as S. cerevisiae, S. pombe, Pichia pastoris, mammalian cells such as COS cells or Chinese hamster ovary (CHO) cells, insect cells, and plant cells such as Arabidopsis thaliana and Nicotiana tabacum. The construct can be introduced into the host cell using any of the techniques commonly known to those skilled in the art. For example, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection and virus-mediated nucleic acid transfer are common methods for introducing nucleic acid into the host cell. In addition, naked DNA can be delivered directly into the cell (e.g., U.S. Patent Nos. 5,580,859 and 5,589,466).

[0050] Polymerase chain reaction (PCR) U.S. Patent Nos. 4,683,202, 4,683,195, 4,800,159 and 4,965,188 disclose conventional PCR techniques. PCR typically uses two oligonucleotide primers that bind to a selected nucleic acid template (e.g., DNA or RNA). Primers useful in some embodiments include oligonucleotides that can act as initiation points for nucleic acid synthesis within the target NG gene nucleic acid sequence described. Primers can be purified from restriction digests by conventional methods or can be synthetically produced. Primers are preferably single-stranded for maximum efficiency in amplification, but primers can also be double-stranded. Double-stranded primers are first denatured, i.e., treated to separate the strands. One method of denaturing double-stranded nucleic acids is by heating.

[0051] If the template nucleic acid is double-stranded, it is necessary to separate the two strands before it can be used as a template in PCR. Strand separation can be achieved by any suitable denaturing method, including physical, chemical, or enzymatic means. One method of separating the nucleic acid strands involves heating until the nucleic acid is predominantly denatured (e.g., greater than 50%, 60%, 70%, 80%, 90%, or 95% denatured). The heating conditions required to denature the template nucleic acid depend, for example, on the buffer salt concentration, as well as the length and nucleotide composition of the nucleic acid to be denatured, but typically range from about 90°C to about 105°C, depending on the characteristics of the reaction, such as temperature and nucleic acid length. Denaturation is typically performed for about 30 seconds to 4 minutes (e.g., 1 minute to 2 minutes and 30 seconds, or 1.5 minutes).

[0052] When the double-stranded template nucleic acid has been denatured by heat, the reaction mixture is cooled to a temperature that promotes annealing of each primer to its target sequence on the target NG gene nucleic acid molecule described. The annealing temperature is usually about 35°C to about 65°C, (e.g., about 40°C to about 60°C, about 45°C to about 50°C). The annealing time can be about 10 seconds to about 1 minute (e.g., about 20 seconds to about 50 seconds, about 30 seconds to about 40 seconds). The reaction mixture is then adjusted to a temperature that promotes or optimizes the activity of the polymerase, i.e., a temperature sufficient for extension to occur from the annealed primers to generate products complementary to the template nucleic acid. The temperature must be sufficient to synthesize an extension product from each primer annealed to the nucleic acid template, but not so high as to denature the extension product from its complementary template (e.g., temperatures for extension generally range from about 40°C to about 80°C (e.g., about 50°C to about 70°C, about 60°C)). Extension times can be from about 10 seconds to about 5 minutes (e.g., from about 30 seconds to about 4 minutes, from about 1 minute to about 3 minutes, from about 1 minute 30 seconds to about 2 minutes).

[0053] PCR assays can use nucleic acids such as RNA or DNA (cDNA). The template nucleic acid does not need to be purified and can be a minor fraction of a complex mixture such as the nucleic acids contained in human cells. Nucleic acid molecules can be extracted from biological samples by conventional techniques such as those described in Diagnostic Molecular Microbiology: Principles and Applications (Persing et al., (eds.), 1993, American Society for Microbiology, Washington DC). Nucleic acids can be obtained from any number of sources, such as plasmids, or natural sources including bacteria, yeast, protozoan viruses, organelles, or higher organisms such as plants or animals.

[0054] The oligonucleotide primers are combined with PCR reagents under reaction conditions conducive to primer extension. For example, a chain extension reaction typically contains 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl2, 0.001% (w / v) gelatin, 0.5-1.0 μg of prototyped template DNA, 50 pmoles of each oligonucleotide primer, 2.5 U of Taq polymerase, and 10% DMSO. The reaction typically contains 150-320 μM each of dATP, dCTP, dTTP, dGTP, or one or more analogs thereof.

[0055] The newly synthesized strands form double-stranded molecules that can be used in subsequent steps of the reaction. The steps of strand separation, annealing, and extension can be repeated as many times as necessary to generate a desired amount of amplification product corresponding to the target nucleic acid molecule. The limiting factors of the reaction are the amount of primers, thermostable enzyme, and nucleoside triphosphates present in the reaction. The cycling steps (i.e., denaturation, annealing, and extension) are preferably repeated at least once. For detection use, the number of cycling steps depends, for example, on the nature of the sample. If the sample is a complex mixture of nucleic acids, more cycling steps will be required to amplify the target sequence enough for detection. Generally, the cycling steps are repeated at least about 20 times, but may be repeated 40, 60, or 100 times.

[0056] Fluorescence Resonance Energy Transfer (FRET) FRET technology (e.g., U.S. Pat. Nos. 4,996,143, 5,565,322, 5,849,489, and 6,162,603) is based on the concept that when a donor fluorescent moiety and a corresponding acceptor fluorescent moiety are placed within a certain distance from each other, energy transfer occurs between two fluorescent moieties that can be visualized or otherwise detected and / or quantified. Typically, the donor transfers energy to the acceptor when excited by light radiation of a suitable wavelength. Typically, the acceptor re-emits the transferred energy in the form of light radiation of a different wavelength. In certain systems, non-fluorescent energy can be transferred between the donor and acceptor moieties via a biomolecule that includes a substantially non-fluorescent donor moiety (see, e.g., U.S. Pat. No. 7,741,467).

[0057] In one example, an oligonucleotide probe can contain a donor fluorescent moiety and a corresponding quencher that may or may not be fluorescent and dissipates the transferred energy in a form other than light. When the probe is intact, energy transfer typically occurs between the donor and acceptor moieties such that the fluorescence emission from the donor fluorescent moiety is quenched by the acceptor moiety. During the extension step of the polymerase chain reaction, the probe bound to the amplification product is cleaved, for example, by the 5' to 3' nuclease activity of Taq polymerase, such that the fluorescence emission of the donor fluorescent moiety is no longer quenched. Exemplary probes for this purpose are described, for example, in U.S. Patent Nos. 5,210,015, 5,994,056, and 6,171,785. Commonly used donor-acceptor pairs include the FAM-TAMRA pair. Commonly used quenchers are DABCYL and TAMRA. Commonly used dark quenchers include BlackHole Quenchers™ (BHQ), (Biosearch Technologies, Inc., Novato, Calif.), Iowa Black™ (Integrated DNA Tech., Inc., Coralville, Iowa), and BlackBerry™ Quencher 650 (BBQ-650) (Berry & Assoc, Dexta, Michigan).

[0058] In another example, two oligonucleotide probes, each containing a fluorescent moiety, can hybridize to the amplification product at a specific position determined by the complementarity of the oligonucleotide probe to the target nucleic acid sequence. When the oligonucleotide probe hybridizes to the amplification product nucleic acid at the appropriate position, a FRET signal is generated. The hybridization temperature can range from about 35°C to about 65°C for about 10 seconds to about 1 minute.

[0059] Fluorescence analysis may be performed, for example, using a photon-counting epifluorescence microscope system (equipped with appropriate dichroic mirrors and filters to monitor a particular range of fluorescence emission), a photon-counting photomultiplier system, or a fluorometer. Excitation to initiate energy transfer or to allow direct detection of the fluorophore can be performed using an argon ion laser, a high-intensity mercury (Hg) arc lamp, a fiber optic light source, or other high-intensity light source appropriately filtered for excitation of the desired range.

[0060] As used herein with respect to a donor moiety and a corresponding acceptor moiety, "corresponding" refers to an acceptor fluorescent moiety or dark quencher that has an absorbance spectrum that overlaps with the emission spectrum of the donor fluorescent moiety. The wavelength maximum of the emission spectrum of the acceptor fluorescent moiety must be at least 100 nm greater than the wavelength maximum of the excitation spectrum of the donor fluorescent moiety. Thus, there can be efficient non-radiative energy transfer between them.

[0061] Fluorescent donor moieties and corresponding acceptor moieties are generally selected for (a) high efficiency Forster energy transfer, (b) large final Stokes shift (>100 nm), (c) shift of emission as far as possible into the red portion of the visible spectrum (>600 nm); and (d) shift of emission to wavelengths higher than the Raman water fluorescence emission produced by excitation at the donor excitation wavelength. For example, a donor fluorescent moiety can be selected that has its maximum excitation wavelength near a laser line (e.g., helium-cadmium 442 nm or argon 488 nm), a high extinction coefficient, a high quantum yield, and good overlap of its fluorescence emission with the excitation spectrum of the corresponding acceptor fluorescent moiety. A corresponding acceptor fluorescent moiety can be selected that has a high extinction coefficient, a high quantum yield, good overlap of its excitation with the emission of the donor fluorescent moiety, and emission in the red portion of the visible spectrum (>600 nm).

[0062] Representative donor fluorescent moieties that can be used with various acceptor fluorescent moieties in FRET technology include fluorescein, lucifer yellow, B-phycoerythrin, 9-acridine isothiocyanate, lucifer yellow VS, 4-acetamido-4'-isothio-cyanatostilbene-2,2'-disulfonic acid, 7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin, succinyl 1-pyrenebutyrate, and 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid derivatives. Representative acceptor fluorescent moieties include LC Red 640, LC Red 705, Cy5, Cy5.5, Lissamine rhodamine B sulfonyl chloride, tetramethylrhodamine isothiocyanate, rhodamine x isothiocyanate, erythrosine isothiocyanate, fluorescein, diethylenetriamine pentaacetate, or other chelates of lanthanide ions (e.g., europium, or terbium), depending on the donor fluorescent moiety used. Donor and acceptor fluorescent moieties can be obtained, for example, from Molecular Probes (Junction City, OR) or Sigma Chemical Co. (St. Louis, MO).

[0063] The donor and acceptor fluorescent moieties can be attached to the appropriate probe oligonucleotide via a linker arm. The length of each linker arm is important since it affects the distance between the donor and acceptor fluorescent moieties. The length of the linker arm can be the distance in angstroms (Å) from the nucleotide base to the fluorescent moiety. Generally, the linker arm is from about 10 Å to about 25 Å. The linker arm can be of the type described in WO 84 / 03285. WO 84 / 03285 also discloses methods of attaching the linker arm to a particular nucleotide base and attaching the fluorescent moiety to the linker arm.

[0064] Acceptor fluorescent moieties such as LC Red 640 can be combined with oligonucleotides containing amino linkers (e.g., C6-amino phosphoramidites available from ABI (Foster City, Calif.) or Glen Research (Sterling, Va.)) to produce, for example, LC Red 640-labeled oligonucleotides. Linkers commonly used to attach donor fluorescent moieties such as fluorescein to oligonucleotides include thiourea linkers (derived from FITC, e.g., Fluorescein-CPG from Glen Research or ChemGene (Ashland, Mass.)), amide-linkers (derived from Fluorescein-NHS-esters, such as CX-Fluorescein-CPG from BioGenex (San Ramon, Calif.)), or 3'-amino-CPG, which requires attachment of the Fluorescein-NHS-ester after oligonucleotide synthesis.

[0065] NG detection The present disclosure provides a method for detecting the presence or absence of NG in a biological or non-biological sample. The provided method avoids the problems of sample contamination, false negatives, and false positives. The method includes performing at least one cycling step, which includes amplifying a portion of a target nucleic acid molecule from a sample using one or more primer pairs, and a FRET detection step. The multiple cycling steps are preferably performed in a thermocycler. The method can be performed using primers and probes to detect the presence of NG, and detection of the target NG gene indicates the presence of NG in the sample.

[0066] As described herein, the amplification product can be detected using a labeled hybridization probe that utilizes FRET technology. One FRET format utilizes TaqMan® technology to detect the presence or absence of the amplification product, and thus the presence or absence of CA. TaqMan® technology utilizes, for example, a single-stranded hybridization probe labeled with a fluorescent dye and a quencher, which may or may not be fluorescent. When the first fluorescent moiety is excited with light of an appropriate wavelength, the absorbed energy is transferred to a second fluorescent moiety or a dark quencher according to the principles of FRET. The second fluorescent moiety is generally a quencher molecule. During the annealing step of the PCR reaction, the labeled hybridization probe binds to the target DNA (i.e., the amplification product) and is degraded during the subsequent extension stage, for example, by the 5' to 3' nuclease activity of Taq polymerase. As a result, the fluorescent moiety and the quencher moiety are spatially separated from each other. As a result, upon excitation of the first fluorescent moiety in the absence of the quencher, fluorescent emission from the first fluorescent moiety can be detected. By way of example, the ABI PRISM® 7700 Sequence Detection System (Applied Biosystems) uses TaqMan® technology and is suitable for carrying out the methods described herein for detecting the presence or absence of NG in a sample.

[0067] Molecular beacons in combination with FRET can also be used to detect the presence of amplification products using real-time PCR. Molecular beacon technology uses a hybridization probe labeled with a first fluorescent moiety and a second fluorescent moiety. The second fluorescent moiety is generally a quencher, and a fluorescent label is typically placed at each end of the probe. Molecular beacon technology uses a probe oligonucleotide with a sequence that allows for secondary structure formation (e.g., a hairpin). The formation of a secondary structure within the probe results in both fluorescent moieties being in spatial proximity when the probe is in solution. After hybridization to the target nucleic acid (i.e., the amplification product), the secondary structure of the probe is disrupted and the fluorescent moieties are separated from each other, so that the emission of the first fluorescent moiety can be detected after excitation with light of an appropriate wavelength.

[0068] Another common form of FRET technology utilizes two hybridization probes. Each probe can be labeled with a different fluorescent moiety and is generally designed to hybridize in close proximity to each other within a target DNA molecule (e.g., an amplification product). A donor fluorescent moiety, e.g., fluorescein, is excited at 470 nm by the light source of the LightCycler® Instrument. During FRET, fluorescein transfers its energy to an acceptor fluorescent moiety, e.g., LightCycler®-Red 640 (LC Red 640) or LightCycler®-Red 705 (LC Red 705). The acceptor fluorescent moiety then emits light of a longer wavelength, which is detected by the optical detection system of the LightCycler® instrument. Efficient FRET can only occur when the fluorescent moieties are in direct local proximity and the emission spectrum of the donor fluorescent moiety overlaps with the absorption spectrum of the acceptor fluorescent moiety. The intensity of the emitted signal can be correlated with the number of original target DNA molecules (e.g., the number of CA genomes). When amplification of the target nucleic acid occurs and an amplification product is produced, the hybridizing step results in a detectable signal based on FRET between the members of the probe pair.

[0069] Generally, the presence of FRET indicates the presence of NG in the sample, and the absence of FRET indicates the absence of NG in the sample. However, insufficient specimen collection, transportation delay, improper transportation conditions, or the use of a specific collection swab (calcium alginate or aluminum shaft) are all conditions that can affect the success and / or accuracy of the test results. Using the method disclosed herein, for example, detection of FRET within 45 cycling steps indicates infection with NG.

[0070] Representative biological samples that can be used to carry out the method include, but are not limited to, respiratory specimens, fecal specimens, blood specimens, skin swabs, nasal swabs, wound swabs, blood cultures, skin and soft tissue infections.The collection and storage methods of biological samples are known to those skilled in the art.Biological samples can be processed (e.g., by nucleic acid extraction methods and / or kits known in the art) to release NG nucleic acid, or in some cases, biological samples can be directly contacted with PCR reaction components and suitable oligonucleotides.

[0071] Melting curve analysis is an additional step that can be included in the cycle profile. Melting curve analysis is based on the fact that DNA melts at a characteristic temperature called the melting temperature (Tm), which is defined as the temperature at which one half of a DNA double strand separates into single strands. The melting temperature of DNA depends mainly on its nucleotide composition. Thus, DNA molecules rich in G and C nucleotides have a higher Tm than DNA molecules rich in A and T nucleotides. By detecting the temperature at which the signal is lost, the melting temperature of the probe can be determined. Similarly, by detecting the temperature at which the signal is generated, the annealing temperature of the probe can be determined. The melting temperature(s) of the probe from the amplification product may confirm the presence or absence of NG in the sample.

[0072] During each thermocycler run, control samples can be cycled as well. A positive control sample can amplify a target nucleic acid control template (other than the amplification product of the described target gene), for example, using control primers and a control probe. A positive control sample can also amplify, for example, a plasmid construct containing a target nucleic acid molecule. Such a plasmid control can be amplified internally (e.g., within the sample) or in a separate sample run alongside the patient sample, using the same primers and probes used to detect the intended target. Such controls are indicative of the success or failure of the amplification, hybridization and / or FRET reaction. Each thermocycler run can also include a negative control, for example, lacking target template DNA. The negative control can measure contamination. This ensures that the system and reagents do not produce false positive signals. Thus, the control reaction can easily determine, for example, the ability of primers to anneal with sequence specificity and initiate extension, as well as the ability of probes to hybridize with sequence specificity and FRET to occur.

[0073] In one embodiment, the method includes a step to avoid contamination. For example, an enzymatic method utilizing uracil-DNA glycosylase is described in U.S. Patent Nos. 5,035,996, 5,683,896 and 5,945,313 to reduce or eliminate contamination between one thermocycling run and the next.

[0074] This method can be carried out using conventional PCR combined with FRET technology. In one embodiment, the LightCycler® instrument is used. The following patent applications: WO 97 / 46707, WO 97 / 46714 and WO 97 / 46712 disclose real-time PCR used with LightCycler® technology.

[0075] The LightCycler® can be operated using a PC workstation and may utilize the Window NT operating system. Signals from samples are obtained as the machine sequentially positions the capillaries over the optical unit. The software may display the fluorescent signal in real time immediately after each measurement. Fluorescence acquisition times range from 10 to 100 milliseconds (msec). After each cycling step, a quantitative display of fluorescence versus cycle number may be continuously updated for all samples. The data generated may be stored for further analysis.

[0076] As an alternative to FRET, double-stranded DNA binding dyes such as fluorescent DNA binding dyes (e.g., SYBR® Green or SYBR® Gold (Molecular Probes)) can be used to detect the amplification products. Upon interaction with double-stranded nucleic acids, such fluorescent DNA binding dyes emit a fluorescent signal after excitation with light of a suitable wavelength. Double-stranded DNA binding dyes such as nucleic acid intercalating dyes can also be used. When using double-stranded DNA binding dyes, a melting curve analysis is usually performed to confirm the presence of the amplification product.

[0077] It is understood that embodiments of the present disclosure are not limited by the configuration of one or more commercially available devices.

[0078] Manufactured products / kits The embodiments of the present disclosure further provide an article of manufacture, composition or kit for detecting NG. The article of manufacture may include primers and probes used to detect target NG genes, together with suitable packaging materials. The composition may include primers used to amplify target NG genes. In certain embodiments, the composition may also include a probe for detecting target NG genes. Representative primers and probes for detecting NG may hybridize to target nucleic acid molecules. Furthermore, the kit may also include appropriately packaged reagents and materials necessary for DNA immobilization, hybridization and detection, such as solid supports, buffers, enzymes and DNA standards. Methods for designing primers and probes are disclosed herein, and representative examples of primers and probes that amplify and hybridize to target nucleic acid molecules are provided.

[0079] The article of manufacture may also include one or more fluorescent moieties for labeling the probe, or may label the probe provided with the kit. For example, the article of manufacture may include donor and / or acceptor fluorescent moieties for labeling the probe. Examples of suitable FRET donor fluorescent moieties and corresponding acceptor fluorescent moieties are provided above.

[0080] The article of manufacture may also include a package insert or packaging label with instructions for using the primers and probes to detect NG in a sample. The article of manufacture and composition may further include reagents (e.g., buffers, polymerase enzymes, cofactors, or agents to prevent contamination) for carrying out the methods disclosed herein. Such reagents may be specific to one of the commercially available instruments described herein.

[0081] Embodiments of the present disclosure are further described in the following examples, which do not limit the scope of the claimed invention. EXAMPLES

[0082] The following examples, tables and figures are provided to aid the understanding of the subject matter, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention. Example 1

[0083] Target selection for NG was the result of a comprehensive search of public sequence databases, as well as a literature search for potential NG targets that identify the closest Neisseria meningitidis and Neisseria lactamica. The selected NG target was the Pilin Inverting Protein (PivNG). NG ) gene targeting, with 7 copies per genome. NG The region contains sequence variants that may affect probe hybridization, but these variants did not contain more than 3 of 7 copies in the sequence database review.

[0084] Real-time PCR detection of NG was performed using either the cobas® 4800 system or the cobas® 6800 / 8800 system platform (Roche Molecular Systems, Inc. Pleasanton, Calif.). The final concentrations of amplification reagents were as follows:

[0085] [Table 2]

[0086] The following table shows a typical thermal profile used in a PCR amplification reaction:

[0087] [Table 3]

[0088] The Pre-PCR program included incubations at 55°C, 60°C and 65°C for initial denaturation and reverse transcription of the RNA template. The three temperature incubations have the advantageous effect that at the lower temperatures even slightly mismatched target sequences (such as genetic variants of an organism) are transcribed, while at the higher temperatures the formation of RNA secondary structures is suppressed, thus resulting in more efficient transcription. The PCR cycling is divided into two runs, both of which apply a one-stage setup (combining annealing and extension). The first five cycles at 55°C allow for increased inclusivity by preamplifying slightly mismatched target sequences, whereas the 45 cycles of the second run increase specificity by using an annealing / extension temperature of 58°C.

[0089] Using the above conditions, Piv NG Gene amplification and detection was performed. The results of an experiment using oligonucleotide primers of SEQ ID NO: 1-2 and oligonucleotide probe of SEQ ID NO: 3 on genomic NG DNA from strain #2949 present at 30,000, 3,000 and 300, 30 and 3 genome equivalent concentrations per PCR reaction (ge / PCR) are shown in Figure 1. Each assay was performed in duplicate and showed an approximate 3.3 cycle difference in signal between 10-fold dilutions of NG strain #2949. Example 2

[0090] NG from 14 strains was used to evaluate the comprehensiveness of the primer / probe combinations of SEQ ID NO:1-3. Samples were extracted with the manual Qiagen kit and quantified by Nanodrop. In all strains, NG was detected at 3.0 e2ge / PCR (Table IV). There was a somewhat wide range of Ct values ​​obtained within each dilution level in the panel, which is likely due to the imprecision of the Nanodrop readout for nucleic acid quantification.

[0091] [Table 4] Example 3

[0092] For NG exclusivity, a panel of 18 strains of commensal Neisseria species was tested (Table V). Samples were purified by manual Qiagen kit and quantified by Nanodrop. No cross-reactivity was observed at 3.0e4 genome copies / PCR (data not shown).

[0093] [Table 5]

[0094] Although the foregoing invention has been described in some detail for clarity and understanding, it will be apparent to those skilled in the art upon reading this disclosure that various changes in form and detail may be made without departing from the true scope of the invention. For example, all of the techniques and devices described above may be used in various combinations. All publications, patents, patent applications, and / or other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, and / or other document was individually indicated to be incorporated by reference for all purposes.

[0095] Informal sequence listing SEQ ID NO: 1R6_1483F_TBBC forward primer CGCAGCATACGCGC SEQ ID NO: 2R6_1483R_TBB reverse primer ATGGCTTTGATGATTTGCGC Probe sequence number 3R6_1483_P TCATCACGCGGCAAAAGATGAAGAAGCGG Sequence number 4Piv NG Gene sequence (GenBank accession number U65994.1, residues 3603 to 4577) TTACGCCGATTTGTAACGCGATGGATCGTAATCTCCGCCTTTCTTATGTACGTGATACGCAATAACGGCGAGTTTACGCATCAATGCTGCGATGATGACTTTTTTAGGCTTCTTCTTTTCTTCCAGCCTTTTGATGAAGTCGGGAAATGCCCTTATCCGGTATGCGACCATGGCCGGCATAAACAAGACGGCGCGTAATTTCCTGTTGCCAAACTTGGTCAGTTTGCCTTTTCCCCTTACGCTTGTCCCGGATTCTTTTTGTTGCGGGCTTAAGCCTGCGAACGCTGCAAATTTGTTTGATGTTTCAAATTTCGAAGATGTTAGATGATGAAACAATACGGCTGCGGTCATTCTGCCTATTGCCGGTATGGTTTCAAGACGCTTCACGCCTTCCTTGCAGTTAGGCTTCTCCGTCTGCTCTTTTATCTTCTCCTTTAAAACTTCAAGCTGTTCATTCATGGCTTTGATGATTTGCGCATATGCTTTGGCCGCTTCTTCATCTTTTGCCGCGTGATGACGGTTTTTCATTGCCGCGCATTCGCTTTTGATTTGCGCGTATGCTGCGGTCATCCGTAAAAGCCTGTATTGCTCGTCCGTAGGCTTCTGCCTCTTTACAAGCTCGCTTTCTTTCGCCAACCGGCAATACTGCGCTATCAGCTTTGCATCCTGTTTGTCTGTTTTGGTTCGCTTGAACCTGCTTTCTGCATACTTGCTTATTTTCAGCGGATTCACTACGTAAACGCTGTAATACTGCGCGAAGTAGTCGGCAACTTCTTCATAATAGTTTCCCGTTGCCTCCATGCAGATATGCAGATTCTGACATCCCAAGCTTTTCAACCGGTCCGAAAACTGATCTAAACCTTTTGAATCGTTGTCAAACTTTGCCGAATGCTCCGTTTTGCCGACCATGGCGGATGCGTTAAAGGTCAGTTTCGATATATCCAATCCTACGGCGTTACGCATGGGATTACCCTT sequence number 5NGDR9 gene sequence CAGCCGCATC ATGATGCCGC ACGTCAGGGC TTCGTCTTCCGATACCTTTGCGCCAGACAA CATCCGGGCG ATGTTTTCTT TTTGCGCTTT TGACCGGGGCG GACAGCCGGTTCCGGTCAAC GTTTCTGACC GTCCCGGCGC GTTTGACGGC GCGTTCCTGC CGCGTTGATTCCTTCGCCGC GCGTTTGGCG GCAAGCATCT GTTTTGCCGT CGGTTTTGTT GCTACTGTTT GCATTTTGTT TTCTCGATTT TTTGATGCCG TTCTCTCAAT GCCCAATCAT AAAGCTGTAT CTCTCACGAG GTCGCCGAAT TTAAATTGAT AGTTCATGTC TTGTTCCATT AATATCAAAC GCAATCTTCA AACACCTCAA TTACATTTTT TAAATCGCTA ATACCATAAT TTATTACATC CTTTAGAAAT TCCAAAGAGG TATCCGCTTC GTCTGCTTTA TCCCTAATT CGTCTATATA ACCCTCTAAC GATTCAGGCT CTTTTAATGC TTCTTTGCAT AAGTTATCTA TTACCCTTAA TGCGTTTTTT ACATCTTCCA AATAGCTCAT TTTTTGCTCC TTAACTCAAA ATGGGATGCT GTCGTCAACA TCTTCTACGG TTTATCTAAT CTGCAAATTC TTCCGCCCT CAATCTTCGC GCCTGCTACT TGCCGACCGC TTTCAATCGC TTTTCTGATG GCGGTTTTGT CCGGTTCGGT TTTGACGGCC TCACGCATAA ATTCGGCGGG GATTTGTGCT TCGTCTAAGATCACGACGGCTTCGGATTTG CGGAACGAGG CTTTAAAAGT GCCGTC

Claims

1. 1. A method for detecting Neisseria gonorrhoeae (NG) in a sample, comprising: A series of NG Piv Ng performing an amplification step comprising contacting gene primers with said sample to generate an amplification product; One or more detectable NG Piv Ng performing a hybridization step comprising contacting a genetic probe with said amplification product; and detecting the presence or absence of the amplification product, the presence of the amplification product indicating the presence of NG in the sample and the absence of the amplification product indicating the absence of NG in the sample. Including, The series of NG Piv Ng the gene primers include a first primer comprising a first oligonucleotide sequence of SEQ ID NO:1 and a second primer comprising a second oligonucleotide sequence of SEQ ID NO:2; The one or more detectable NG Piv Ng The method, wherein the genetic probe comprises a third oligonucleotide sequence of SEQ ID NO: 3 or its complement.

2. 2. The method of claim 1 , The hybridization step converts the amplification product into a detectable NG Piv labeled with a donor fluorescent moiety and a corresponding acceptor moiety. Ng contacting with a genetic probe; The method, wherein the detecting step comprises detecting the presence or absence of fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor moiety of the probe, the presence or absence of fluorescence indicating the presence or absence of NG in the sample.

3. The method of claim 2, wherein the amplifying step uses a polymerase enzyme that has 5'-3' nuclease activity.

4. The method of claim 2 or 3, wherein the donor fluorescent moiety and the corresponding acceptor moiety are within 8 to 20 nucleotides of each other on the probe.

5. The method of claim 2 , wherein the acceptor moiety is a quencher.

6. 6. The method of claim 1, wherein the oligonucleotide sequences of the first primer and the second primer each comprise at least one modified nucleotide.

7. The at least one modified nucleotide is N 6 -benzyl-dA,N 4 -benzyl-dC,N 6 -para-tert-butyl-benzyl-dA, and N 4 -para-tert-butyl-benzyl-dC.

8. 8. The method of claim 1, further comprising contacting the sample with a set of primers and probes for amplification and detection of NGDR9 gene sequences.

9. A kit for detecting nucleic acids of Neisseria gonorrhoeae (NG), comprising: a first primer comprising a first oligonucleotide sequence of SEQ ID NO:1; a second primer comprising a second oligonucleotide sequence of SEQ ID NO:2; and - a fluorescently detectably labeled probe comprising a third oligonucleotide sequence of SEQ ID NO: 3 or its complement, wherein the detectably labeled probe is configured to hybridize to an amplicon generated by said first primer and said second primer.

10. The kit of claim 9 , wherein the detectably labeled third oligonucleotide sequence comprises a donor fluorescent moiety and a corresponding acceptor moiety.

11. The kit of claim 10 , wherein the acceptor moiety is a quencher.

12. 12. The kit of claim 9, further comprising at least one of a nucleoside triphosphate, a nucleic acid polymerase, and a buffer required for the function of the nucleic acid polymerase.

13. 13. The kit of any one of claims 9 to 12, wherein the oligonucleotide sequences of the first primer, the second primer, and the fluorescently detectably labeled probe comprise at least one modified nucleotide.

14. 14. The kit of any one of claims 9 to 13, wherein the oligonucleotide sequences of the first primer, the second primer, and the fluorescently detectably labeled probe have 40 or fewer nucleotides.

15. 15. The kit of claim 9, wherein the oligonucleotide sequences of the first primer and the second primer each comprise at least one type of modified nucleotide.

16. The at least one modified nucleotide is N 6 -benzyl-dA,N 4 -benzyl-dC,N 6 -para-tert-butyl-benzyl-dA, and N 4 -para-tert-butyl-benzyl-dC.

17. 17. The kit of any one of claims 9 to 16, further comprising a set of primers and probes for the amplification and detection of NGDR9 gene sequences.

Citation Information

Patent Citations

  • neisseria gonorrhoeae specific oligonucleotide sequences

    JP2009533023A

  • Methods and reagents for detecting neisseria gonorrhoeae and its antimicrobial resistance determinants

    WO2016086305A1